Influence of CYP2D6 Genotype on Metoprolol Plasma Concentration and β-Adrenergic Inhibition During Long-Term Treatment: A Comparison With Bisoprolol

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Journal of Cardiovascular Pharmacology

• Publication date

  2005-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/01.fjc.0000184117.76188.68PMID 16220080
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Haplotypes of CYP3A4 and their close linkage with CYP3A5 haplotypes in a Japanese population

  2004cited by this paper
• Effect of CYP2D6*10 on pharmacokinetic variability of routinely administered metoprolol in middle-aged and elderly Japanese patients

  2003cited by this paper
• Pharmacological properties of the naturally occurring Ala(457)Pro variant of the human norepinephrine transporter.

  2002cited by this paper
• CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants.

  2002cited by this paper
• CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants.

  2002cited by this paper
• Effect of the CYP2D6 genotype on metoprolol metabolism persists during long-term treatment.

  2002cited by this paper
• Plasma concentrations of haloperidol are related to CYP2D6 genotype at low, but not high doses of haloperidol in Korean schizophrenic patients.

  2001cited by this paper
• CYP2D6 genotypes in a Japanese population: low frequencies of CYP2D6 gene duplication but high frequency of CYP2D6*10.

  2000cited by this paper
• Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)

  1999cited by this paper
• Pharmacokinetics of metoprolol enantiomers in Chinese subjects of major CYP2D6 genotypes

  1999influential reference
• Analysis of the CYP2D6 gene in relation to dextromethorphan O‐demethylation capacity in a Japanese population

  1999cited by this paper
• The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.

  1999cited by this paper
• Stereoselective metabolism of bisoprolol enantiomers in dogs and humans.

  1998influential reference
• Pharmacokinetics and metabolism of bisoprolol enantiomers in humans.

  1998cited by this paper
• Relationships between acute and chronic beta-blocking effects of bisoprolol in healthy volunteers: a practical approach to predict intensity of beta-blockade.

  1994cited by this paper
• Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians.

  1994cited by this paper
• Heart Disease: A Textbook of Cardiovascular Medicine

  1992cited by this paper
• Increased onset of sudden cardiac death in the first three hours after awakening.

  1992cited by this paper
• Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S‐mephenytoin

  1992cited by this paper
• Polymorphic debrisoquin hydroxylation in 757 Swedish subjects

  1988cited by this paper
• Low frequency of slow debrisoquine hydroxylation in a native Chinese population.

  1987cited by this paper
• Pharmacodynamic profile of bisoprolol, a new beta 1-selective adrenoceptor antagonist.

  1986cited by this paper
• Circadian variation in the frequency of onset of acute myocardial infarction.

  1985cited by this paper
• Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations

  1985cited by this paper
• Comparison of two long-acting preparations of metoprolol with conventional metoprolol and atenolol in healthy men during chronic dosing.

  1982cited by this paper
• Oxidation phenotype--a major determinant of metoprolol metabolism and response.

  1982cited by this paper
• Plasma levels and effects of metoprolol on blood pressure, adrenergic beta receptor blockade, and plasma renin activity in essential hypertension

  1976cited by this paper
• Plasma levels and effects of metoprolol on blood pressure and heart rate in hypertensive patients after an acute dose and between two doses during long‐term treatment

  1975cited by this paper
• Letter: Testicular feminisation and inguinal hernia.

  1973cited by this paper

• Validating the accuracy of mathematical model–based pharmacogenomics dose prediction with real-world data

  2025cites this paper
• Why Bisoprolol? A Neglected Beta-Blocker in the U.S.

  2024cites this paper
• Comparison between the ECG Outcomes of Metoprolol and Bisoprolol.

  2023cites this paper
• Preemptive Pharmacogenetic-Guided Metoprolol Management for Postoperative Atrial Fibrillation in Cardiac Surgery: The Preemptive Pharmacogenetic-Guided Metoprolol Management for Atrial Fibrillation in Cardiac Surgery Pilot Trial.

  2023cites this paper
• Sex-Based Difference in the Effect of Metoprolol on Heart Rate and Bradycardia in a Population-Based Setting

  2022cites this paper
• Impact of the CYP2D6 Genotype on Metoprolol Tolerance and Adverse Events in Elderly Chinese Patients With Cardiovascular Diseases

  2022cites this paper
• Chromosomal Region 11p14.1 is Associated with Pharmacokinetics and Pharmacodynamics of Bisoprolol

  2022cites this paper
• Acute liver injury induced by drug interaction between dacomitinib and metoprolol due to the inhibition of CYP2D6 by dacomitinib

  2022cites this paper
• The effect of rs776746 polymorphism in the CYP3A5 gene on heart rate when using bisoprolol in patients with acute coronary syndrome

  2022cites this paper
• Patient Age and CYP2D6*4/CYP2D6*3 Genotype on Maximal Heart Rate in Patients after Acute Coronary Syndrome Treated with Bisoprolol

  2021cites this paper
• Influence of CYP2D6 and CYP3A5 Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Bisoprolol in Hypertensive Chinese Patients

  2021cites this paper
• Beta-blockers in COPD: A systematic review based on recent research.

  2020cites this paper
• Examination of Metoprolol Pharmacokinetics and Pharmacodynamics Across CYP2D6 Genotype‐Derived Activity Scores

  2020cites this paper
• Population pharmacokinetic analysis of bisoprolol in type 2 diabetic patients with hypertension

  2020cites this paper
• Bisoprolol responses (PK/PD) in hypertensive patients: A cytochrome P450 (CYP) 2D6 targeted polymorphism study

  2020cites this paper
• CYP2D6 polymorphism and its impact on the clinical response to metoprolol: A systematic review and meta-analysis.

  2020cites this paper
• Population pharmacokinetic analysis of bisoprolol in type 2 diabetic patients with hypertension

  2020cites this paper
• Azilsartan medoxomil.

  2020cites this paper
• Population pharmacokinetics of metoprolol in Chinese post-PCI patients

  2020cites this paper
• Population Pharmacokinetic Analysis of Bisoprolol in Patients With Acute Coronary Syndrome

  2019cites this paper
• Pharmacogenomics And Hypertension: Current Insights

  2019cites this paper
• CYP2D6 Genotype-guided Metoprolol Therapy in Cardiac Surgery Patients: Rationale and Design of the Pharmacogenetic-guided Metoprolol Management for Postoperative Atrial Fibrillation in Cardiac Surgery (PREEMPTIVE) Pilot Study.

  2019cites this paper
• Comparative research on the metabolism of metoprolol by four CYP2D6 allelic variants in vitro with LC-MS/MS.

  2019cites this paper
• PGPM_A_230201 341..359

  2019cites this paper
• Factors influencing hepatic metabolism of antihypertensive drugs: impact on clinical response

  2019cites this paper
• Pharmacogenetic testing by polymorphic markers G1846A (CYP2D6*4) and C100T (CYP2D6*10) of the CYP2D6 gene in coronary heart disease patients taking ββ-blockers in the Republic of Sakha (YAKUTIA)

  2018cites this paper
• Population Pharmacokinetic Analysis of Bisoprolol in Patients with Stable Coronary Artery Disease

  2018cites this paper
• Associations of polymorphisms of CYP2D6 and CYP2C9 with early onset severe pre-eclampsia and response to labetalol therapy

  2018cites this paper
• CYP2D6 Genetic Variation and Beta-Blocker Maintenance Dose in Patients with Heart Failure

  2017cites this paper
• Beta blocker dialyzability and effectiveness in chronic hemodialysis patients

  2016cites this paper
• Pharmacological modification of the perioperative stress response in noncardiac surgery.

  2016cites this paper
• Impact of β-blocker selectivity on long-term outcomes in congestive heart failure patients with chronic obstructive pulmonary disease

  2015cites this paper
• Personalized medicine: importance of clinical interpretative skills for real-world patient care.

  2014cites this paper
• Impact of CYP2D6 polymorphisms on clinical efficacy & tolerability of metoprolol tartrate

  2014cites this paper
• The controversy of peri-operative ß-blockade: what should I do?

  2014cites this paper
• Cardiovascular pharmacogenetics of antihypertensive and lipid- lowering therapies.

  2014cites this paper
• Modulation of cardiac cytochrome P450 in patients with heart failure

  2014cites this paper
• Implementation of pharmacogenetics in evidence-based medicine: Toward advancing personalized medicine

  2014cites this paper
• Unexpectedly high blood concentration of bisoprolol after an incorrect prescription: A case report.

  2013cites this paper
• Cytochrome P450 2D6 phenotype and genotype in hypertensive patients on long-term therapy with metoprolol.

  2013cites this paper
• Medicinal chemistry of antimigraine drugs.

  2013cites this paper
• Pharmacogenomics and heart failure in congenital heart disease.

  2013cites this paper
• Risk of Emergent Bradycardia Associated with Initiation of Immediate‐ or Slow‐Release Metoprolol

  2013cites this paper
• The relationship between plasma concentration of metoprolol and CYP2D6 genotype in patients with ischemic heart disease

  2013cites this paper
• The pharmacogenetics of β-adrenergic receptor antagonists in the treatment of hypertension and heart failure

  2012cites this paper
• Interpretation of Urine drug Test for Pain Clinic: Methodology and Metabolism pathways of controlled substance

  2012cites this paper
• Pharmacogenomics of Cardiovascular Drugs

  2012cites this paper
• Clinical application of cardiovascular pharmacogenetics.

  2012cites this paper
• Pharmacogenetics of β-Blockers

  2012cites this paper
• Population pharmacokinetics of bisoprolol in patients with chronic heart failure

  2012cites this paper
• The role of β-blockers in the management of hypertension: An Asian perspective

  2011cites this paper
• Translating pharmacogenetics to primary care

  2011cites this paper
• Genetic variation, β-blockers, and perioperative myocardial infarction.

  2011cites this paper
• Safety of perioperative β-blocker use: how do β-blockers compare in terms of side effects?

  2011cites this paper
• Commentary The role of b-blockers in the management of hypertension: An Asian perspective

  2011cites this paper
• Predicting differential drug response using demographic-based variation in gene expression profiles

  2011cites this paper
• Pharmacogenomics of Cardiovascular Drugs and Adverse Effects in Pediatrics

  2011cites this paper
• Multimorbidity and polypharmacy: Which betablocker to use in relation to the pharmacokinetic profile and interaction potential

  2010influential citation
• Issues in drug metabolism of major antihypertensive drugs: β-blockers, calcium channel antagonists and angiotensin receptor blockers

  2010cites this paper
• Relation of ADRB1, CYP2D6, and UGT1A1 polymorphisms with dose of, and response to, carvedilol or metoprolol therapy in patients with chronic heart failure.

  2010cites this paper
• Analysis of Interindividual Variability and Race Difference in the Pharmacokinetics of .BETA.-blocker for Personalized Medicine in Heart Failure Patients

  2009cites this paper
• Impact of the CYP2D6 Genotype on the Clinical Effects of Metoprolol: A Prospective Longitudinal Study

  2009cites this paper
• β-Blocker pharmacogenetics in heart failure

  2008cites this paper
• CYP2D6 a jeho klinický význam

  2008cites this paper
• Pharmacogenetics of β‐Blockers

  2007cites this paper
• Pharmacogenetics of beta-blockers.

  2007cites this paper
• CYP2D6 A JEHO KLINICKÝ V ÝZNAM CYP2D6 A JEHO KLINICKÝ V ÝZNAM

  2007cites this paper
• Cytochrome P450: another player in the myocardial infarction game?

  2007cites this paper
• Pharmacokinetics and pharmacodynamics of bisoprolol in rats with bilateral ureter ligation-induced renal failure.

  2006cites this paper
• Multiple regression analysis of pharmacogenetic variability of carvedilol disposition in 54 healthy Japanese volunteers.

  2006cites this paper